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Insulin resistance and protein 
catabolism in non-diabetic 
hemodialysis patients
AJ O’Sullivan1,2 and JJ Kelly1
 Chronic kidney disease (CKD) is associated with complex metabolic 
changes including insulin resistance. Siew et al. have highlighted an 
important relationship between insulin resistance and skeletal muscle 
protein turnover. If insulin resistance is implicated in sarcopenia of CKD, 
further research will be required to determine whether interventions 
that improve insulin sensitivity improve clinical outcomes and 
cardiovascular risk in CKD.
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One of the most important predictive fac-
tors of survival on dialysis is the presence 
of malnutrition.1,2 Previous studies have 
demonstrated that a signifi cant propor-
tion of hemodialysis patients and chronic 
ambulatory peritoneal dialysis patients 
are malnourished. Th ese patients have 
increased morbidity and mortality and 
a poorer quality of life as compared with 
patients who are adequately nourished. 
Impaired nutrition may be measured by 
a variety of methods, but those methods 
that measure body composition directly 
(total-body nitrogen analysis and dual-
energy X-ray absorptiometry) demon-
strate that lean body mass is reduced in 
patients with renal impairment.3,4 Th ese 
changes are demonstrable at the initia-
tion of dialysis and are likely to develop 
in patients with mild to moderate chronic 
kidney disease (CKD). Negative nitro-
gen balance and sarcopenia can result 
from decreased protein anabolism or 
increased protein catabolism or both. 
Th e balance between these factors and 
relative contributions of other condi-
tions that cause sarcopenia are still to be 
defi ned. Decreased protein anabolism 
may result from disuse of muscles, sub-
optimal protein intake, intercurrent ill-
ness, and medications, whereas increased 
protein catabolism can result from acido-
sis, microinfl ammatory processes related 
to increased cytokines, oxidative stress, 
and the reduced actions of anabolic hor-
mones such as insulin.
Th e increased mortality and morbidity 
observed in dialysis patients with malnu-
trition or depleted muscle mass are princi-
pally due to an increase in cardiovascular 
events.5 In view of this, it is important 
not only to understand the mechanisms 
by which sarcopenia may occur, but also 
to understand the association between 
altered body composition and clinical out-
comes in CKD. Recent literature has high-
lighted the eff ects of chronic infl ammation 
and oxidative stress in predisposing CKD 
patients to malnutrition and increased vas-
cular disease.6 Chronic infl ammation may 
predispose to impaired nutritional status 
by enhancing protein catabolism. Asso-
ciations between chronic infl ammation, 
measured as elevated C-reactive protein 
or proinfl ammatory cytokines, impaired 
nutritional status, and subclinical and 
clinically overt vascular disease, have been 
documented in patients at the commence-
ment of dialysis. Furthermore, systemic 
infl ammation may result in reductions in 
total cholesterol levels, which may account 
for the altered epidemiological association 
of an inverse relationship between total 
cholesterol levels and mortality reported 
by some investigators in dialysis patients.
Although the malnutrition, inflam-
mation, atherosclerosis hypothesis may 
explain many of the clinical associations 
of malnutrition in dialysis patients,6 CKD 
is associated with complex metabolic 
changes, and Siew et al.7 (this issue) now 
highlight the importance of another meta-
bolic eff ect of CKD — insulin resistance. 
It is well documented that insulin resist-
ance is a feature of advanced CKD, and 
there is some evidence that insulin resist-
ance occurs in mild to moderate CKD. 
Th e cause of insulin resistance in non-
diabetic CKD is not apparent, but it may 
be related to central adiposity, the micro-
infl ammatory environment, or other met-
abolic defects. Insulin resistance has been 
shown to be an independent predictor of 
survival in dialysis patients.8 It has been 
hypothesized that insulin resistance may 
increase vascular risk in dialysis patients 
in the same way observed in the general 
population, because of the tendency of 
vascular risk factors to cluster in subjects 
who are insulin resistant.
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Siew et al.7 have highlighted another 
important eff ect of insulin resistance in 
CKD, namely its eff ect on skeletal muscle 
protein turnover. Previously this group 
showed that hemodialysis patients with 
poorly controlled diabetes mellitus have 
reduced skeletal mass and increased 
protein breakdown. This led them to 
hypothesize that insulin resistance was an 
important determinant of protein break-
down, and therefore they aimed to assess 
whether insulin resistance was a major 
determinant of protein breakdown in non-
diabetic patients with CKD.
In a technically demanding and elegant 
study, Siew et al.7 have demonstrated a 
direct association between a marker of 
insulin resistance — the homeostasis 
model assessment (HOMA) index — and 
increased protein catabolism in skeletal 
muscle. These changes were reported 
in a group of non-obese, non-diabetic 
patients who had been stable on dialysis 
(mean duration of treatment of 6 years) 
and in whom there was no evidence of 
chronic infl ammation as indicated by a 
C-reactive protein level within the nor-
mal range. Interestingly, skeletal muscle 
breakdown was greater than skeletal 
muscle synthesis, leading to a negative 
balance of skeletal muscle turnover, 
whereas whole-body protein turnover did 
not reveal signifi cant diff erences between 
protein synthesis and breakdown. When 
skeletal muscle synthesis and breakdown 
were correlated with HOMA, there 
was a significant positive correlation, 
and a significant negative correlation 
with muscle protein balance, suggesting 
that sarcopenia of CKD is related to insu-
lin resistance.
A limitation of this study is the quan-
tifi cation of insulin resistance using the 
surrogate index of HOMA, and these 
findings need to be confirmed using 
eu glycemic clamp techniques. The 
absence of chronic infl ammation in this 
cohort raises the question of whether 
such changes occur uniformly in dialysis 
patients or whether diff erent mechanisms 
of muscle wasting (and perhaps vascular 
risk) may operate in diff erent dialysis 
patients. Th ese observations suggest an 
alternative pathway of malnutrition and 
vascular disease in CKD in which insu-
lin resistance has a central role (Figure 
1). In this model, insulin resistance may 
contribute both to sarcopenia through 
increased protein catabolism and to 
atherosclerosis mediated by traditional 
cardiovascular risk factors, even in the 
absence of chronic infl ammation.
Although Siew et al.7 have shown an 
association between insulin resistance 
and muscle protein balance, causality has 
not been established in this report. Th ere 
is animal evidence to suggest that insu-
lin resistance is actually a contributor to 
increased muscle breakdown, as treat-
ment with rosiglitazone reduces insulin 
resistance and leads to a suppression 
of proteolysis.9 Moreover, whole-body 
protein catabolism is elevated in poorly 
controlled diabetic patients and improves 
with eff ective treatment.10 It is unclear 
why insulin resistance would have a sig-
nifi cant eff ect on skeletal muscle balance 
and not whole-body protein balance, 
and this observation requires further 
research. In animal and human mod-
els, it is well established that insulin has 
anabolic actions on protein turnover. A 
recent study reports a strong correlation 
between insulin resistance, rate of pro-
tein catabolism, and gluconeogenesis.10 
Th ese fi ndings suggest that insulin-resist-
ant subjects acquire amino acids from 
protein catabolism for increased hepatic 
gluconeogenesis and glucose output.
Th e observations reported by Siew et 
al.7 are intriguing and need to be retested 
in a larger cohort of subjects. Th e pos-
sible compounding eff ects of age, sex, 
ethnicity, and medications on measure-
ments of insulin resistance need to be 
considered, by comparison of dialysis 
patients with appropriate control sub-
jects. Furthermore, if insulin resistance 
is important in the pathogenesis of mus-
cle wasting in CKD, one would expect 
that these results will also be substanti-
ated in subjects with mild to moderate 
CKD, in whom reduced muscle mass has 
also been reported.4 If insulin resistance 
is causally implicated in the sarcopenia 
and increased vascular risk of CKD, it 
provides a potential therapeutic target 
for the treatment of these abnormali-
ties. Further research will be required 
to determine whether interventions 
that improve insulin sensitivity improve 
clinical outcomes in CKD.
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Figure 1 | Potential pathological factors contributing to reduced muscle mass and negative 
nitrogen balance in chronic kidney disease on dialysis. Nitrogen and muscle accretion depends 
on the relationship between protein catabolism and anabolism. Factors that promote anabolism, 
such as anaerobic exercise and adequate protein intake, are reduced in renal failure because of 
factors such as reduced fitness and lethargy, and anorexia, respectively. Factors that promote 
catabolism, such as acidosis, inflammation, and insulin resistance, are increased in chronic kidney 
disease. The resultant negative nitrogen balance leads to sarcopenia, which increases morbidity and 
mortality, the latter further increased by insulin resistance and the microinflammatory environment.
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